Drug Trial Radar · NCT07552077
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Apr 2026
Primary completion
Aug 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Palvella Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and effectiveness of the experimental drug PTX-022 in the treatment of angiokeratomas
Conditions
- Angiokeratomas
Interventions
PTX-022Drug
topical administration of PTX-022
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse EventsTime frame: 3 months
- Overall Angiokeratoma Investigator Global Assessment (AK-IGA)Time frame: 3 months
- Overall Patient Global Impression of Change (PGI-C)Time frame: 3 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Unified Health
Sherman Oaks, California · Not yet recruiting
Cleaver Medical Group
Dawsonville, Georgia · Recruiting
Vividia Dermatology
Las Vegas, Nevada · Not yet recruiting
Epiphany Dermatology
Southlake, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.